These results reveal a CHK2-YBX1/YBX3 complex-mediated immune suppression mechanism, suggesting that targeting YBX1 and its complexes in GBM may have clinical potential in combination with ICB therapy (24). This evidence concerns the gene YBX3 and glioblastoma.